Alpharmaxim full lockup logo

Newborn screening is essential to improve diagnosis and outcomes

Maintaining the voice of rare diseases in a new, virtual world: Insights from the European Conference on Rare Diseases (ECRD) 2020

Newborn screening is essential to improve diagnosis and outcomes

Alpharmaxim work closely with industry to provide education around newborn screening and can help to drive awareness of newborn screening panels. It is important to increase the number of newborn screening panels and harmonise their number and size across Europe. Newborn screening:

  • Allows for early diagnosis and, therefore, management of rare genetic diseases
  • Could have a significant impact on the burden on healthcare systems and patients/families
  • Could lead to a reduction in later misdiagnosis and suffering

Be prepared to truly demonstrate your commitment to the rare disease field, particularly in these uncertain times.

At Alpharmaxim, we have extensive experience in helping speciality healthcare companies across the world communicate with healthcare professionals and patients, particularly in rare diseases. We are passionate about helping our clients tell their stories and fulfil their promises, and we aim to make a real difference to patients, families and healthcare professionals.

If you would like to know more, please visit our website, or contact Sophie Jones on +44 (0)161 929 0400.